Role of Nuclear Tyrosine Rak in Breast Cancer
Role of Nuclear Tyrosine Rak in Breast Cancer
批准号:
7011198
负责人:
FUNDA MERIC-BERNSTAM
金额:
$6.8万
依托单位国家:
美国
项目类别:
财政年份:
2001
资助国家:
美国
项目状态:
已结题
起止时间:
2001-08-03 至 2006-07-31
关键词:
MCF7 cellapoptosisathymic mousebreast neoplasmscell cycleepidermal growth factorgene deletion mutationgene therapygrowth factor receptorsimmunocytochemistryimmunoprecipitationmetastasisneoplasm /cancer therapynonhuman therapy evaluationprotein tyrosine kinasetransfection /expression vectortumor necrosis factor alphawestern blottings
中文摘要
描述(由申请方提供):酪氨酸激酶是调节蛋白
在细胞生长和分化中起着重要作用。 初步
工作中,酪氨酸激酶在乳腺癌细胞系中的表达,
与正常样乳腺细胞相比,
展示分析 核酪氨酸激酶Rak表达下调与否
在几种乳腺癌细胞系中表达。 此外,腺病毒
早期基因E1A,已知可抑制乳腺癌细胞的生长
lines,上调Rak表达。 Rak在乳腺中的表达增强
癌细胞具有生长抑制活性,这是通过
集落形成效率 令人惊讶的是,很少有人知道
细胞中的Rak及其作用机制。 这项提案将考验
假设Rak抑制肿瘤细胞生长,
Rak在乳腺癌中起作用。 首先,Rak表达对
肿瘤细胞生长将在体外通过细胞计数、殖民地
形成测定和软琼脂测定,并在体内测试。 二是
Rak对乳腺癌细胞凋亡敏感性及对乳腺癌细胞增殖的影响
将研究细胞周期。 Rak临界域的贡献
将通过缺失和突变分析来研究其功能。 第三、
Rak在不同级别和转移性乳腺癌中的表达
将通过免疫组织化学分析来确定电位。 这些研究
将描述Rak在细胞生长中的作用及其作用机制。
从科学的角度来看,确定Rak的作用机制将
这将极大地提高我们对细胞生长是如何调节的理解。 从
从临床角度来看,Rak可能是一个有用的预后标志物,
治疗剂。 此外,确定Rak在肿瘤生长中的作用将使
我们可以更好地定制酪氨酸激酶抑制剂用于
临床试验
英文摘要
DESCRIPTION (provided by applicant): Tyrosine kinases are regulatory proteins
that play a central role in cell growth and differentiation. In preliminary
work, the expression of tyrosine kinases in breast cancer cell lines was
compared to normal-like breast cells using a tyrosine kinase differential
display assay. The nuclear tyrosine kinase Rak was downregulated or not
expressed in several breast cancer cell lines. Furthermore, the adenovirus
early gene E1A, which is known to inhibit the growth of breast cancer cell
lines, upregulated Rak expression. Enhanced expression of Rak in breast
cancer cells had a growth suppressing activity as measured by a decrease in
colony formation efficiency. Surprisingly, little is known about the role of
Rak in cells and its mechanism of action. This proposal will test the
hypothesis that Rak inhibits tumor cell growth, and that loss of expression of
Rak plays a role in breast cancer. First, the effect of Rak expression on
tumor cell growth will be assessed in vitro by cell counts, the colony
formation assay and the soft agar assay, and tested in vivo. Second, the
effect of Rak on the sensitivity of breast cancer cells to apoptosis and on
the cell cycle will be studied. The contribution of critical domains of Rak
to its function will be studied by deletion and mutation analysis. Third,
expression of Rak in breast cancers of various grades and metastatic
potentials will be determined by immunohistochemical analysis. These studies
will delineate the role of Rak in cell growth and its mechanism of action.
From a scientific standpoint, determining Rak's mechanism of action will
significantly enhance our understanding of how cell growth is regulated. From
a clinical standpoint, Rak may be a useful prognostic marker, and a gene
therapy agent. Furthermore, identifying Rak's role in tumor growth will allow
us to better tailor the specificity of tyrosine kinase inhibitors used in
clinical trials.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Discovery of the next-generation RET-targeted drugs based on nicotinamide scaffold
-
批准号:10652630
-
项目类别:
-
资助金额:$56.79万
-
财政年份:2022
-
负责人:FUNDA MERIC-BERNSTAM
-
依托单位:
Research Project 3: Optimizing DNA damage repair-targeted combination therapy
-
批准号:10242642
-
项目类别:
-
资助金额:$21.81万
-
财政年份:2017
-
负责人:FUNDA MERIC-BERNSTAM
-
依托单位:
Evaluating drug combinations, efficacy and adaptive feedback in KRAS inhibition
-
批准号:10200357
-
项目类别:
-
资助金额:$12.0万
-
财政年份:2017
-
负责人:FUNDA MERIC-BERNSTAM
-
依托单位:
University of Texas PDX Development and Trial Center
-
批准号:9985264
-
项目类别:
-
资助金额:$144.75万
-
财政年份:2017
-
负责人:FUNDA MERIC-BERNSTAM
-
依托单位:
University of Texas PDX Development and Trial Center
-
批准号:10681971
-
项目类别:
-
资助金额:$55.76万
-
财政年份:2017
-
负责人:FUNDA MERIC-BERNSTAM
-
依托单位:
Research Project 3: Optimizing DNA damage repair-targeted combination therapy
-
批准号:10681972
-
项目类别:
-
资助金额:$10.77万
-
财政年份:2017
-
负责人:FUNDA MERIC-BERNSTAM
-
依托单位:
University of Texas PDX Development and Trial Center
-
批准号:10242641
-
项目类别:
-
资助金额:$125.97万
-
财政年份:2017
-
负责人:FUNDA MERIC-BERNSTAM
-
依托单位:
Targeting mTOR for Cancer Therapy
-
批准号:6856714
-
项目类别:
-
资助金额:$24.6万
-
财政年份:2005
-
负责人:FUNDA MERIC-BERNSTAM
-
依托单位:
Targeting mTOR for Cancer Therapy
-
批准号:7339039
-
项目类别:
-
资助金额:$23.33万
-
财政年份:2005
-
负责人:FUNDA MERIC-BERNSTAM
-
依托单位:
Targeting mTOR for Cancer Therapy
-
批准号:7174303
-
项目类别:
-
资助金额:$23.33万
-
财政年份:2005
-
负责人:FUNDA MERIC-BERNSTAM
-
依托单位:
Targeting mTOR for Cancer Therapy
-
批准号:7540995
-
项目类别:
-
资助金额:$23.33万
-
财政年份:2005
-
负责人:FUNDA MERIC-BERNSTAM
-
依托单位:
Targeting mTOR for Cancer Therapy
-
批准号:7004523
-
项目类别:
-
资助金额:$24.02万
-
财政年份:2005
-
负责人:FUNDA MERIC-BERNSTAM
-
依托单位:
Role of Nuclear Tyrosine Rak in Breast Cancer
-
批准号:6844312
-
项目类别:
-
资助金额:$13.61万
-
财政年份:2001
-
负责人:FUNDA MERIC-BERNSTAM
-
依托单位:
Role of Nuclear Tyrosine Rak in Breast Cancer
-
批准号:6522694
-
项目类别:
-
资助金额:$6.8万
-
财政年份:2001
-
负责人:FUNDA MERIC-BERNSTAM
-
依托单位:
Role of Nuclear Tyrosine Rak in Breast Cancer
-
批准号:6358705
-
项目类别:
-
资助金额:$13.61万
-
财政年份:2001
-
负责人:FUNDA MERIC-BERNSTAM
-
依托单位:
Role of Nuclear Tyrosine Rak in Breast Cancer
-
批准号:6712744
-
项目类别:
-
资助金额:$13.61万
-
财政年份:2001
-
负责人:FUNDA MERIC-BERNSTAM
-
依托单位:
Role of Nuclear Tyrosine Rak in Breast Cancer
-
批准号:6630441
-
项目类别:
-
资助金额:$13.61万
-
财政年份:2001
-
负责人:FUNDA MERIC-BERNSTAM
-
依托单位:
15 Developmental Therapeutics
-
批准号:10655559
-
项目类别:
-
资助金额:$1.87万
-
财政年份:1996
-
负责人:FUNDA MERIC-BERNSTAM
-
依托单位:
NIH INTRAMURAL NRSA INSTITUTIONAL TRAINING PROGRAM
-
批准号:2196351
-
项目类别:
-
资助金额:$3.02万
-
财政年份:1995
-
负责人:FUNDA MERIC-BERNSTAM
-
依托单位:
NIH INTRAMURAL NRSA INSTITUTIONAL TRAINING PROGRAM
-
批准号:2196350
-
项目类别:
-
资助金额:$2.89万
-
财政年份:1994
-
负责人:FUNDA MERIC-BERNSTAM
-
依托单位:
国内基金
海外基金
登录
查看更多内容
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
-
批准号:LBY21H010001
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2020
-
负责人:郑绪阳
-
依托单位:
去乙酰化酶SIRT1在前体mRNA可变剪切中的作用及其生理病理效应研究
-
批准号:31970691
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2019
-
负责人:张胜萍
-
依托单位:
TM9SF4调控非小细胞肺癌细胞凋亡机制研究
-
批准号:31900527
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2019
-
负责人:孙磊
-
依托单位:
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
-
批准号:81703335
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2017
-
负责人:卫高菲
-
依托单位:
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
-
批准号:81670594
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2016
-
负责人:陈昊
-
依托单位:
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
-
批准号:81470791
-
项目类别:面上项目
-
资助金额:73.0万元
-
批准年份:2014
-
负责人:董家鸿
-
依托单位:
Apoptosis signal-regulating kinase 1是七氟烷抑制小胶质细胞活化的关键分子靶点?
-
批准号:81301123
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2013
-
负责人:王海莲
-
依托单位:
姜黄素与TRAIL的协同抗肿瘤机制研究
-
批准号:31101223
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2011
-
负责人:曹林
-
依托单位:
转凝蛋白通过线粒体凋亡途径致足细胞凋亡的机制研究
-
批准号:81100502
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2011
-
负责人:管娜
-
依托单位:
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
-
批准号:81101529
-
项目类别:青年科学基金项目
-
资助金额:22.0万元
-
批准年份:2011
-
负责人:陈雪芹
-
依托单位: